Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

Inclusion Criteria: * Treated acute HIV-1 infection (initiated HAART during the acute retroviral syndrome AND were diagnosed by a positive HIV-1 viral load and a negative or indeterminate Western blot) * Minimum of 6 months of HAART, defined as 2 or more antiretroviral drugs in combination * At least three CD4 cell counts over 350 cells/mm3 for a period of 6 months prior to study entry * Screening CD4 cell count over 350 cells/mm3 within 30 days prior to study entry * HIV-1 RNA levels over 50 copies/ml for a period of 6 months prior to study entry * Screening HIV-1 RNA level less than 50 copies/ml within 30 days prior to study entry * Agrees to use acceptable methods of contraception Exclusion Criteria: * History of serious adverse reactions to vaccines * History of CD4 cell count less than 250 cells/mm3, opportunistic infections, or AIDS-defining illnesses. Patients who have had one CD4 count less than 250 cells/mm3 or who have had CD4 counts less than 250 cells/mm3 for not more than 2 weeks during acute infection are not excluded. * History of autoimmune disease, immunodeficiency, asthma, diabetes requiring insulin or oral hypoglycemics, thyroid disease, bleeding disorder, active malignancy, viral hepatitis, or asplenia * Positive HBV, HCV, or syphilis test * Suspected allergy or adverse reaction to any component of the study agent * Changes in antiretroviral regimen within 6 months prior to entry due to virologic failure (not including toxicities) * Previous participation in STIs * Pregnancy or breast-feeding * Live attenuated vaccines or investigational research agents within the 30 days prior to study entry * Blood products within the 120 days prior to study entry * Immunoglobulin within the 60 days prior to study entry * Subunit or killed vaccines or allergy treatments with antigen injections within the 14 days prior to study entry * Prior experimental HIV vaccines * Certain immunosuppressive medications within the 6 months prior to study entry * Current TB prophylaxis or therapy * Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements * Serious illness requiring systemic treatment and/or hospitalization. An individual who has either completed therapy OR is clinically stable for at least 14 days prior to study entry is eligible. * Anti-dsDNA antibody greater than the upper limit of normal